公开(公告)号：US12129522B2

公开(公告)日：2024-10-29

申请号：US17816087

申请日：2022-07-29

申请人： H. Lee Moffitt Cancer Center and Research Institute, Inc.

发明人： Mokenge P. Malafa ,  Jennifer Permuth ,  Dung-Tsa Chen

IPC分类号： C12Q1/6886

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178

摘要： The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion. Microarray containing miRNAs indicative of the presence of pancreatic cancer, or having a high risk of pancreatic cancer development, particularly, in a subject having a pancreatic lesion, and methods of use of the microarrays are also provided.

公开(公告)号：US12128254B2

公开(公告)日：2024-10-29

申请号：US18531960

申请日：2023-12-07

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

发明人： Brian P. Tonner

IPC分类号： A61N5/10 ,  A61B6/50 ,  A61B6/58

CPC分类号： A61N5/1049 ,  A61N5/1048 ,  A61N5/1064 ,  A61B6/508 ,  A61B6/583 ,  A61N2005/1051 ,  A61N2005/1059 ,  A61N5/1071 ,  A61N2005/1087

摘要： The accuracy charged-particle beam trajectories used for radiation therapy in patients is improved by providing feedback on the beam location within a patient's body or a quality assurance phantom. Particle beams impinge on a patient or phantom in an arrangement designed to deliver radiation dose to a tumor, while avoiding as much normal tissue as can be achieved. By placing fiducial markers in the tumor or phantom that contain specific atomic constituents, a detection signal consisting of atomic fluorescence is produced by the particle beam. An algorithm can combine the detected fluorescence signal with the known location of the fiducial markers to determine the location of the particle beam in the patient or phantom.

公开(公告)号：US20240308971A1

公开(公告)日：2024-09-19

申请号：US18668678

申请日：2024-05-20

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

发明人： Nupam MAHAJAN ,  Nicholas LAWRENCE

IPC分类号： C07D333/38

CPC分类号： C07D333/38

摘要： Disclosed are WEE1 inhibitors and their use in methods of inhibiting a WEE1 epigenetic activity or treating cancer having WEE1 epigenetic activity.

公开(公告)号：US20240299544A1

公开(公告)日：2024-09-12

申请号：US18569178

申请日：2022-06-16

申请人： Health Research, Inc. ,  H. Lee Moffitt Cancer Center and Research Institute, Inc.

发明人： Pawel KALINSKI ,  Brian CZERNIECKI

IPC分类号： A61K39/00 ,  A61K31/415 ,  A61K31/713 ,  C07K16/28 ,  C12N5/0784

CPC分类号： A61K39/4615 ,  A61K31/415 ,  A61K31/713 ,  A61K39/4622 ,  A61K39/464406 ,  C07K16/2827 ,  C12N5/0639 ,  A61K2039/505 ,  C12N2501/056 ,  C12N2501/2301 ,  C12N2501/24 ,  C12N2501/25

摘要： Provided are compositions and methods for prophylaxis or therapy of cancer. The compositions comprise α-type-1 dendritic cells that have been treated with intact proteins that comprise cancer antigens, or peptides that comprise cancer antigens, or combinations thereof. The approaches can also include adding a chemokine-modulating regimen.

公开(公告)号：US20240299519A1

公开(公告)日：2024-09-12

申请号：US18653312

申请日：2024-05-02

申请人： H. Lee Moffitt Cancer Center and Research Institute, Inc.

发明人： Marco L. Davila

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61K47/65 ,  C07K14/705 ,  C07K14/725 ,  C07K16/08 ,  C07K16/28

CPC分类号： A61K39/001129 ,  A61K39/3955 ,  A61K47/65 ,  C07K14/7051 ,  C07K14/70578 ,  C07K16/087 ,  C07K16/2896 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/33

摘要： Disclosed are compositions and methods for targeted treatment of CD99-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CD99-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CD99-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. Also disclosed are multivalent antibodies are disclosed that are able to engage T-cells to destroy CD99-expressing malignant cells.

公开(公告)号：US12077590B2

公开(公告)日：2024-09-03

申请号：US16487372

申请日：2018-02-22

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

发明人： Marco L. Davila

IPC分类号： C07K16/28

CPC分类号： C07K16/283 ,  C07K2317/622

摘要： Disclosed are compositions and methods for gene transfer in immune effector cells, e.g. to create chimeric antigen receptors (CARs). In particular, polypeptides are disclosed that comprising an antigen-binding region and a heparin binding domain, wherein the antigen-binding region is capable of specifically binding to an immune cell antigen located on an immune effector cell, and wherein the heparin binding domain is capable of binding a viral vector.

公开(公告)号：US20240208940A1

公开(公告)日：2024-06-27

申请号：US18556241

申请日：2022-04-19

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

发明人： Haitao JI

IPC分类号： C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K47/55 ,  A61P35/00 ,  C07D405/14 ,  C07D409/14 ,  C07D471/10 ,  C07D487/04

CPC分类号： C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K47/55 ,  A61P35/00 ,  C07D405/14 ,  C07D409/14 ,  C07D471/10 ,  C07D487/04

摘要： Described herein are small molecule inhibitors of the β-catenin/B-cell lymphoma 9 interaction and pharmaceutical compositions including a therapeutically effective amount of the small molecule inhibitors described herein. Described are also methods of treating oncological disorders, for example cancer by administering the small molecule inhibitors of the β-catenin/B-cell lymphoma interaction described herein.

公开(公告)号：US20240197761A1

公开(公告)日：2024-06-20

申请号：US18555582

申请日：2022-04-18

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

发明人： Eric K. LE-LAU

IPC分类号： A61K31/7004 ,  A61K35/17 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K31/7004 ,  A61K35/17 ,  A61K39/3955 ,  A61P35/00

摘要： Disclosed are methods for treating infectious diseases and cancers comprising administering to a subject a L-fucose.

公开(公告)号：US20240192195A1

公开(公告)日：2024-06-13

申请号：US18554500

申请日：2022-04-11

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

发明人： Ariosto S. SILVA ,  Praneeth SUDALAGUNTA ,  Kenneth SHAIN ,  Rafael Renatino CANEVAROLO ,  Mark B. MEADS

IPC分类号： G01N33/50 ,  C12Q1/6886 ,  G16B20/00 ,  G16B40/20 ,  G16H10/20 ,  G16H20/10 ,  G16H30/40

CPC分类号： G01N33/5011 ,  C12Q1/6886 ,  G16B20/00 ,  G16B40/20 ,  G16H10/20 ,  G16H20/10 ,  G16H30/40 ,  C12Q2600/106 ,  C12Q2600/158

摘要： Disclosed are methods for identifying a gene regulatory network and treatment regimens combined with MM standard of care drugs to either delay, or reverse resistance to the standard of care therapy. Also disclosed is a synergy between Selinexor (SELI) and dexamethasone (DEX), pomalidomide (POM), elotuzumab (ELO), and daratumumab (DARA), and expression signatures and mutations associated with response to these agents.

公开(公告)号：US11987568B2

公开(公告)日：2024-05-21

申请号：US17265649

申请日：2019-08-02

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

发明人： Nupam Mahajan ,  Nicholas Lawrence

IPC分类号： C07D333/38

CPC分类号： C07D333/38

摘要： Disclosed is a method for selecting a cancer therapeutic for a patient that involves assaying a tumor biopsy sample from the subject to detect PAXIP1 expression, and selecting a WEE1 inhibitor as the cancer therapeutic if PAXIP1 is detected in the tumor biopsy sample.